{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-125309","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2025-12-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.631703+00:00","generated_at":"2026-05-16T11:53:55.599997+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verastem discontinues RAMP 203 (KRAS G12C) trial; pivots to VS-7375 for KRAS G12D","bullets":["Discontinues RAMP 203 (KRAS G12C) trial in advanced NSCLC; focuses on VS-7375 (KRAS G12D inhibitor).","As of Nov 26, 2025: doublet in G12C-naive patients achieved ORR 40% (12/30), mPFS 11.1 months.","Previously G12C-treated patients in doublet: ORR 9.5% (2/21), mPFS 3.7 months.","Triplet combo: ORR 50% (2/4) in naive; 36% (4/11) tumor reduction in pretreated.","VS-7375 showed 69% ORR (11/16) in KRAS G12D NSCLC; no DLTs observed across RAMP 203."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-125309","json":"https://secwatch.observer/filing/0001104659-25-125309.json","markdown":"https://secwatch.observer/filing/0001104659-25-125309.md","text":"https://secwatch.observer/filing/0001104659-25-125309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925125309/0001104659-25-125309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925125309/tm2534532d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:53:55.599997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}